# Belapectin

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Belapectin
> Markdown URL: https://mediated.wiki/source/Belapectin.md
> Source: https://en.wikipedia.org/wiki/Belapectin
> Source revision: 1303594802
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

{{Infobox drug
| drug_name         = Belapectin
| synonyms          = {{ubl|GR-MD-02|Galactoarabino-rhamnogalacturonate}}
| INN               =
| type              = <!-- empty -->
| image             =
| alt               =
| caption           =
<!-- Clinical data -->
| pronounce         =
| tradename         =
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration =
| ATCvet            =
| ATC_prefix        = <!-- 'none' if uncategorised -->
| ATC_suffix        =
<!-- Legal status -->
| legal_AU          = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_comment  =
| legal_BR          = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C5, D1, D2, E, F1, F2, F3, F4 -->
| legal_BR_comment  =
| legal_CA          = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment  =
| legal_DE          = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment  =
| legal_NZ          = <!-- Class A, B, C -->
| legal_NZ_comment  =
| legal_UK          = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment  =
| legal_US          = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_US_comment  =
| legal_EU          =
| legal_EU_comment  =
| legal_UN          = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment  =
| legal_status      = Investigational
<!-- Pharmacokinetic data -->
| bioavailability   =
| protein_bound     =
| metabolism        =
| metabolites       =
| onset             =
| elimination_half-life =
| duration_of_action=
| excretion         =
<!-- Identifiers -->
| CAS_number        = 1980787-47-0
| CAS_number2       = 1604015-18-0
| UNII              = K7ODU55HT6
| PubChem           =
| DrugBank          = DB15125
<!-- Chemical and physical data -->
| IUPAC_name        = α-<small>D</small>-Galacturono-α-<small>D</small>-galacto-β-<small>D</small>-galacto-6-deoxy-α-<small>L</small>- manno-α-<small>L</small>-arabinan, (1→2),(1→3),(1→4)-, methyl ester
| chemical_formula  =
| molecular_weight  =
}}

'''Belapectin''' (also known as GR-MD-02) is a [galectin-3](/source/galectin-3) inhibitor developed by [Galectin Therapeutics](/source/Galectin_Therapeutics) for the treatment of [non-alcoholic steatohepatitis](/source/non-alcoholic_steatohepatitis).<ref>{{cite journal |last1=Al Attar |first1=Atef |last2=Antaramian |first2=Ani |last3=Noureddin |first3=Mazen |title=Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis |journal=Expert Review of Clinical Pharmacology |date=3 April 2021 |volume=14 |issue=4 |pages=457–464 |doi=10.1080/17512433.2021.1894127|pmid=33612037 }}</ref><ref>{{Cite journal |last1=Kram |first1=Michael |date=Feb 27, 2023 |title=Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis |journal=World J Hepatol |volume=15 |issue=2 |pages=201–207 |doi=10.4254/wjh.v15.i2.201 |pmid=36926236 |pmc=10011901 |doi-access=free }}</ref><ref>{{cite journal |last1=Slack |first1=R.J. |last2=Mills |first2=R. |last3=Mackinnon |first3=A.C. |title=The therapeutic potential of galectin-3 inhibition in fibrotic disease |journal=The International Journal of Biochemistry & Cell Biology |date=January 2021 |volume=130 |article-number=105881 |doi=10.1016/j.biocel.2020.105881|doi-access=free |pmid=33181315 }}</ref><ref>{{cite journal |last1=Tapper |first1=Elliot B. |last2=Ufere |first2=Nneka N. |last3=Huang |first3=Daniel Q. |last4=Loomba |first4=Rohit |title=Review article: current and emerging therapies for the management of cirrhosis and its complications |journal=Alimentary Pharmacology & Therapeutics |date=May 2022 |volume=55 |issue=9 |pages=1099–1115 |doi=10.1111/apt.16831 |pmid=35235219 |url=https://doi.org/10.1111/apt.16831 |language=en |issn=0269-2813|pmc=9314053 }}</ref> In a phase 2b/3 trial belapectin at 2 mg/kg/LBW reduces varices development in MASH cirrhosis with portal hypertension.<ref>{{Cite journal |date=10 May 2025 |title=Belapectin at 2 mg/kg/LBW reduces varices development in MASH cirrhosis with portal hypertension: results from the NAVIGATE trial |url=https://www.easlcongress.eu/wp-content/uploads/2025/04/EASL-Congress-2025-_-LB-Abstracts.pdf |journal=EASL Congress |volume=2025}}</ref>

==References==
{{reflist}}

Category:Lectins
Category:Experimental drugs developed for non-alcoholic fatty liver disease

{{pharma-stub}}

---
Adapted from the Wikipedia article [Belapectin](https://en.wikipedia.org/wiki/Belapectin) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/Belapectin?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.